Clin2
NCT07502339Possibly a fitNot yet recruiting

Upadacitinib for severe ulcerative colitis in hospital

UC - Ulcerative Colitis

Treatments studied

Part of Digestive system clinical trials.

This trial tests a medication called upadacitinib for people hospitalized with a severe ulcerative colitis flare. It could help control inflammation and reduce symptoms.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 4
Enrollment
50 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You must be between 18 and 75 years old and currently hospitalized for a severe flare of ulcerative colitis.
  • You must have had ulcerative colitis for at least 3 months, confirmed by a colonoscopy and tissue sample.
  • You cannot have had a colectomy (surgery to remove the colon) or a stoma/pouch.
  • You must not have had a blood clot in your leg or lung in the past year.
  • You cannot have taken upadacitinib before, or have certain infections or weak immune system.
  • Women who could become pregnant must use effective birth control and not breastfeed.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06332534Recruiting· Phase 3
Upadacitinib in children with moderate to severe Crohn's disease

This study tests an oral pill called upadacitinib for children with moderate to severe Crohn's disease that hasn't responded well to other treatments. It aims to see if the medicine can reduce inflammation and improve symptoms safely.

Oakland, California
NCT07700446Not yet recruiting· Phase 4
Testing a second round of upadacitinib for ulcerative colitis

This trial tests if a higher dose of upadacitinib can help people with ulcerative colitis who stopped responding to the 30 mg daily dose. It aims to see if re-inducing with a stronger dose can bring back symptom control.

NCT07550673Recruiting· Phase 4
Upadacitinib vs. Infliximab for Severe Ulcerative Colitis

This study compares two medications—upadacitinib and infliximab—as second-line treatments for acute severe ulcerative colitis (a serious flare of inflammatory bowel disease). The trial will help doctors understand which treatment works better when standard first-line therapy hasn't controlled the inflammation.

Ankang, Shaanxi
NCT06660693Recruiting· Phase 3
Comparing rescue treatments for severe ulcerative colitis flare

This trial tests two different medicines, infliximab and upadacitinib, to see which works better for people with severe ulcerative colitis that hasn't improved after 3 days of IV steroids. The goal is to find the best rescue option to help you feel better and avoid surgery.

Hamilton, Ontario
NCT06780683Recruiting
Testing upadacitinib for inflammatory bowel disease

This study tests a medication called upadacitinib for people with inflammatory bowel disease (ulcerative colitis or Crohn's). The goal is to see how well it works and if it's safe.

Guangzhou, Guangdong
NCT07546097Recruiting· Phase 4
Upadacitinib vs Steroids for Severe Ulcerative Colitis

This study compares a newer medication called upadacitinib to traditional steroids for treating acute severe ulcerative colitis (sudden worsening of UC with bloody diarrhea and urgent symptoms). The goal is to see which approach works better as a first treatment.

Ankang, Shaanxi

Hear when a new UC - Ulcerative Colitis trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.